Please assess the completion status of the following clinical trial:

Trial Title: Treatment of GLP-1 for Diabetic Bariatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Candidates for Roux-en-Y Gastric Bypass Surgery with an established diagnosis of Type 2 diabetes requiring insulin treatment for glycemic control~2. Ability to provide informed consent before any trial-related activities~Exclusion Criteria:~1. Prior metabolic surgery procedure~2. Use of GLP-1 analogues for diabetes treatment at the time of recruitment~3. Known or suspected allergy to semaglutide or the excipients in semaglutide, or related products.~4. Contraindications to semaglutide which include a personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia syndrome-2 (MEN-2)~5. Previously randomized for participation in this trial.~6. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures.~7. Type 1 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: PLACEBO_COMPARATOR): Once weekly injection of placebo 4-6 months at prescribed dose
- Test Arm (Type: ACTIVE_COMPARATOR): Once weekly injection of 1.0mg Semaglutide 4-6 months at prescribed dose

Based on this trial design, predict the completion outcome and termination type (if applicable).